Leerink Swann Reiterates Outperform On Rigel Pharma As Shares Plunge 12+% On Missed R343 Trial Endpoints
August 26, 2013 at 12:02 PM EDT
Shares of Rigel Pharma (NASDAQ: RIGL ) have traded down around 12-13 percent throughout Monday morning's trading session following some concerning data from a trial of its R343 . Rigel shares have bounced sharply from the pre-market low under $2.50. Analyst Marko Kozul at Leerink Swann, a firm which specializes
